Imfinzi Approved in China for Stage III Non-Small Cell Lung Cancer

December 26, 2019

China’s National Medical Products Administration approved AstraZeneca’s Imfinzi (durvalumab) to treat Stage III non-small cell lung cancer (NSCLC) in patients whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (CRT).

The approval was based on results of a phase 3 clinical trial, in which Imfinzi reduced the risk of death by 32 percent and prolonged the time patients lived without disease progression or death by more than 11 months.

Imfinzi is approved for unresectable, Stage III NSCLC after CRT in 54 countries and regions, including the U.S., Japan and across the EU.

View today's stories